Nanobac Pharmaceuticals, Inc. announced last year a sharpened focus in three areas: 1) developing safe and effective drug therapies for diseases where soft tissue calcification, or "calcium deposits," is a dominant feature, 2) validating the Company's antibody and antigen derived diagnostics to determine levels of calcification, and 3) scientific studies to determine the infectious nature of the calcifying nano particles (CNPs).
The sharpened focus on drug therapies led to a Pre-IND (Investigational New Drug) meeting with the FDA on January 19, 2007. With positive results from this meeting, the Company is moving forward with the IND application for Chronic prostatitis/Chronic pelvic pain syndrome (CP/CPPS) also referred to as category III prostatitis. In the United States, more than 2 million men per year visit their physician for prostatitis. Nanobac's strategic partner at the Cleveland Clinic will be the principal investigator for the clinical trial portion of this IND.
The sharpened focus on determining if there is an infectious nature to CNPs is through collaborative efforts with the Mayo Clinic and investigators at China's Coal Medical College. These studies are scheduled to conclude in June. If successful, they will establish that CNPs are a causative agent in the formation of calcific diseases, and in the specific case of the China study, Gall Stones. It also suggests that CNPs might play a similar role in the formation of kidney stones, prostatic stones and could be the agent involved with the calcification stage of atherosclerosis.
Full Story >>
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment